Stifel reaffirms Buy on Dianthus Therapeutics (DNTH) with 186% upside, focusing on DNTH103 success.

From Yahoo Finance: 2025-06-21 15:50:00

Dianthus Therapeutics, Inc. (NASDAQ:DNTH) is highlighted as one of the best small company stocks to invest in. Stifel reaffirmed a Buy rating with a price target of $52.00, indicating an upside of 186.3%. The company is developing lead drug candidate DNTH103 for myasthenia gravis, with Phase 2 trial results expected in September 2025.

Dianthus Therapeutics, Inc. (NASDAQ:DNTH) is focusing on the design and potential success of DNTH103 in treating myasthenia gravis. The company aims to differentiate itself from competitors with a more favorable safety profile and a user-friendly dosing schedule. A follow-up Biologics License Application may follow if the MG trial and CIDP study go well.

Dianthus Therapeutics, Inc. (NASDAQ:DNTH) is a New York-based biotechnology company founded in 2019. It specializes in developing complement therapeutics for autoimmune and inflammatory diseases. The company’s lead drug candidate, DNTH103, is currently undergoing clinical trials for various indications, showing promise for future treatments.

A biopharmaceutical team is working on developing new compounds in the laboratory for therapeutic purposes. Big changes are anticipated for Dianthus Therapeutics, Inc. as it plans to test DNTH103 in chronic inflammatory demyelinating polyneuropathy, with interim results expected in the second quarter of 2026. This study could pave the way for future applications of the drug.

While Dianthus Therapeutics, Inc. (NASDAQ:DNTH) shows investment potential, some AI stocks offer greater upside potential with lower downside risk. Investors looking for undervalued AI stocks may benefit from exploring other options. For those interested in AI investments, consider researching the best short-term AI stock for potential opportunities.



Read more at Yahoo Finance: Stifel Reaffirms Buy on Dianthus Therapeutics, Inc. (DNTH) with 186% Upside